Endonovo Therapeutics, Inc. (ENDV)

Endonovo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	0.26	0.14	0.07	0.17	0.31	0.08
Revenue Growth (YoY)	1699.85%	85.15%	-55.91%	-46.55%	272.51%	-
Cost of Revenue	0.01	0.01	0.01	0.07	0.09	0.01
Gross Profit	0.25	0.13	0.06	0.1	0.22	0.07
Selling, General & Admin	2.86	3.39	2.28	2.36	3.22	3.31
Research & Development	-	-	-	0	0.15	0.27
Operating Expenses	2.86	3.39	2.28	3.01	4.03	4.23
Operating Income	-2.62	-3.26	-2.23	-2.91	-3.81	-4.16
Interest Expense	-1.22	-1.32	-0.94	-2.08	-6.09	-5.2
Other Non Operating Income (Expenses)	-0.73	-14.25	0.04	5.16	-7.49	2.6
EBT Excluding Unusual Items	-4.56	-18.84	-3.13	0.16	-17.39	-6.75
Other Unusual Items	0.16	0.36	0.02	-0.56	0.07	0.32
Pretax Income	-4.4	-18.47	-3.1	-0.4	-17.31	-6.44
Earnings From Continuing Operations	-4.4	-18.47	-3.1	-0.4	-17.31	-6.44
Net Income	-4.4	-18.47	-3.1	-0.4	-17.31	-6.44
Net Income to Common	-4.4	-18.47	-3.1	-0.4	-17.31	-6.44
Shares Outstanding (Basic)	255	139	60	12	1	0
Shares Outstanding (Diluted)	255	139	60	12	1	0
Shares Change (YoY)	130.88%	132.64%	389.83%	1651.87%	92.38%	49.72%
EPS (Basic)	-0.02	-0.13	-0.05	-0.03	-24.83	-17.76
EPS (Diluted)	-0.06	-0.13	-0.05	-0.03	-24.83	-17.76
Free Cash Flow	-0.63	-0.68	-0.99	-0.74	-2.54	-2.89
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.06	-3.65	-7.97
Gross Margin	96.21%	92.62%	79.50%	60.57%	69.89%	84.47%
Operating Margin	-1023.16%	-2411.69%	-3045.68%	-1756.49%	-1228.08%	-4995.33%
Profit Margin	-1722.23%	-13649.17%	-4247.17%	-238.60%	-5582.37%	-7729.53%
Free Cash Flow Margin	-246.32%	-501.52%	-1349.54%	-447.29%	-820.08%	-3468.29%
EBITDA	-1.97	-2.62	-1.58	-2.26	-3.16	-3.51
D&A For EBITDA	0.65	0.65	0.65	0.65	0.65	0.65
EBIT	-2.62	-3.26	-2.23	-2.91	-3.81	-4.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.